Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25915491 | 0.93 | MAPK1 (0.37) | MAPK1ATMKDM4EALDH1A1TSHR | |
| SCHEMBL25915486 | 0.91 | MAPK1 (0.38) | MAPK1ATMKDM4EALDH1A1TSHR | |
| SCHEMBL25915430 | 0.91 | MAPK1 (0.38) | MAPK1ATMKDM4EALDH1A1TSHR | |
| SCHEMBL25915487 | 0.91 | MAPK1 (0.38) | MAPK1ATMKDM4EALDH1A1TSHR | |
| SCHEMBL25915489 | 0.90 | MAPK1 (0.37) | MAPK1ATMKDM4EALDH1A1TSHR | |
| SCHEMBL25915432 | 0.90 | MAPK1 (0.39) | MAPK1ATMKDM4EALDH1A1TSHR | |
| SCHEMBL25915482 | 0.89 | MAPK1 (0.38) | MAPK1ATMKDM4EALDH1A1TSHR | |
| SCHEMBL25915189 | 0.87 | MAPK1 (0.34) | MAPK1ATMKDM4EALDH1A1TSHR | |
| SCHEMBL24126475 | 0.86 | KDM4E (0.35) | MAPK1ATMKDM4E | |
| SCHEMBL25915428 | 0.84 | MAPK1 (0.36) | MAPK1ATMKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230240134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-07-27 | — | — | US | disclosed |
| US-20230240134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230240134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | MAPK1 681/4885ATM 3135/4885KDM4E 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.